Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Greg Baker/AFP via Getty Images
DNA sequencing company Illumina is purchasing Pacific Biosciences for $1.2 billion in an effort to corner the market in cutting-edge genetic research, Illumina CEO Francis deSousa announced in an interview with Forbes that published Thursday.
Why it matters: This is the largest deal Illumina has made in its history. The company had a $46 billion market capitalization ahead of the deal, and believes the acquisition could lead to more growth and market expansion resulting in what deSousa called "a more perfect view of the genome."